Yixintang Pharmaceutical Group (002727) Fair Value & Analysis
Healthcare · CN · Market cap 6.4B CNY
Fair value as of: Jul 22, 2026
From 26 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from ¥18.92 to ¥9.45 (−50.1%) since Jun 25, 2026. Share price +11.5% over the past month.
A solid business, but screening 17% overvalued on our models.
What matters now
- Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.
- Our model range runs from ¥7.09 (bear) to ¥11.81 (bull), base ¥9.45. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 65/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range ¥9.59 – ¥43.27 · fair‑value band ¥7.09 – ¥11.81 · the ¥11.36 price screens above the ¥9.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Yixintang Pharmaceutical Group (002727) currently trades at ¥11.36, while our model-based Fair Value estimate is ¥9.45, implying the stock looks roughly 16.8% overvalued today. The Quality Score stands at 65/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Yixintang Pharmaceutical Group generated revenue of 17.0B CNY at a net margin of 1.6%. Revenue declined 7.0% year over year. It earns a return on equity of 3.7%. The balance sheet holds a net cash position of 1.4B CNY. Fundamentals as of Jul 22, 2026
Our scenario range runs from ¥7.09 (bear case) to ¥11.81 (bull case); at ¥11.36, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 32% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -17%, 002727 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥37.30) versus Earnings-Based (¥6.46). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Yixintang Pharmaceutical Group Co., Ltd., together with its subsidiary, engages in the pharmaceutical retail chain and pharmaceutical distribution business.
Full company description
Yixintang Pharmaceutical Group Co., Ltd., together with its subsidiary, engages in the pharmaceutical retail chain and pharmaceutical distribution business. The company is involved in the wholesale, retail, leasing, and operation of medical devices; sale of food, disinfectants, disinfection equipment, sanitary products and disposable medical products, household appliances, adult toys, agricultural and sideline products, cosmetics, and daily sundries and necessities; manufacturing of glasses; provision of value-added telecommunications, Internet live broadcast technology, and Internet information services for medicines, as well as clinic and foot bath services; operation of aquatic wild animals and call center; retail of publications; and decoction services for Chinese herbal medicines. It also engages in the agency sale of single-purpose commercial prepaid cards and China sports lottery; and maternal and child care activities. In addition, the company provides health care, housekeeping, amusement park, residents' daily life, and health consulting service, as well as business agency, ticket agency, personal Internet live broadcast, remote health management, corporate member points management, food delivery, and road freight transportation services. Further, it is involved in the import and export of goods and technology; wholesale of pet food and supplies; and wholesale of clothing and accessories. Additionally, the company sells products online. The company was formerly known as Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd. and changed its name to Yixintang Pharmaceutical Group Co., Ltd. in June 2019. Yixintang Pharmaceutical Group Co., Ltd. was founded in 2000 and is headquartered in Kunming, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Yixintang Pharmaceutical Group reported revenue of ¥17.3B in FY2025 versus ¥14.6B in FY2021, a compound +4.4%/yr. Reported net income was ¥263M in FY2025, compounding −26.9%/yr from FY2021.
002727 screens 17% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 61 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.24 | ¥29.07 | +44% |
| DaShenLin Pharmaceutical Group 603233 | ¥17.81 | ¥23.86 | +34% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.51 | ¥10.57 | -8% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
| ShuYu Civilian Pharmacy Corp 301017 | ¥13.34 | ¥5.91 | -56% |
Compare Yixintang Pharmaceutical Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Yixintang Pharmaceutical Group (002727) overvalued or undervalued?
What is the fair value of 002727?
What is the quality score of 002727?
What is the revenue of Yixintang Pharmaceutical Group (002727)?
What is the net profit margin of 002727?
Does Yixintang Pharmaceutical Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Yixintang Pharmaceutical Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.